Cellaviva becomes an independent company under NextCell Pharma

Cellaviva, the stem cell bank operated by NextCell Pharma AB, has announced its transition to an independentcompany. This strategic move will enable Cellaviva to further focus on its core mission of providing expectant parents with the opportunity to preserve and store valuable stem cells collected from the placenta and umbilical cord. These cells, which would otherwise be discarded post-birth, offer significant potential for future medical treatments and therapies.

Since its inception in August 2015, Cellaviva has garnered a growing customer base each year, reflecting increasing awareness and demand for stem cell preservation services. This growth trajectory has positioned Cellaviva to successfully operate as a separate limited company effective September 1, 2024, while remaining a wholly owned subsidiary of NextCell Pharma AB.

Incoming CEO of Cellaviva Sofie Falk Jansson will outline her vision and strategic plans for the company's future in a presentation scheduled for 09:00 today, Wednesday, June 5. The presentation will be available for live streaming and for later viewing via the provided link:

https://www.redeye.se/events/1014540/investor-update-nextcell-pharma

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: [phone]
E-mail: [e-mail]
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma

For more information about Cellaviva, please contact
Sofie Falk Jansson, Head of Cellaviva
Tel: [phone]
E-mail: [e-mail]
Website:www.cellaviva.se

Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser.

About NextCell Pharma AB

NextCell is a cell therapy company that is in phase 2 studies with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase 3 study. ProTrans is manufactured utilizing the patented platform technology for selection of optimal cells with potency to treat inflammatory disorders including autoimmune diseases. NextCell owns Cellaviva, the largest stem cell bank in the Nordics and QVance, a quality analysis CRO company in start up.

https://news.cision.com/nextcell-pharma-ab/r/cellaviva-becomes-an-independent-company-under-nextcell-pharma,c3995297

https://mb.cision.com/Main/15834/3995297/2844929.pdf

(c) 2024 Cision. All rights reserved., source Press Releases - English